Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 18,289 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Double Blind Clear all

Conditions: Fibromyalgia
Interventions: Placebo, Milnacipran 100mg; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,025 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 24
States / cities: Tuscaloosa, Alabama • Fresno, California • Pismo Beach, California + 20 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: anamorelin HCl, placebo; Drug
Lead sponsor: Helsinn Therapeutics (U.S.), Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 19
States / cities: Little Rock, Arkansas • Melbourne, Florida • Augusta, Georgia + 12 more

Conditions: Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions: RT001, Vehicle Comparator; Drug · Other
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 30 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: San Francisco, California • New York, New York • White Plains, New York

Conditions: Liver Transplant
Interventions: treprostinil sodium, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Neurological Disorder
Interventions: Glyceryl Tribenzoate; Drug
Lead sponsor: Forest Hills Lab; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Bloomfield, New Jersey

Conditions: Asthma
Interventions: Montelukast, Sugar pill; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Parkinson Disease
Interventions: sumanirole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years and older
Enrollment: 854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 69
States / cities: Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 60 more

Conditions: Healthy
Interventions: Citicoline, Placebo; Dietary Supplement
Lead sponsor: Kirin Holdings Company, Limited; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Canfield, Ohio

Conditions: Depressive Disorder
Interventions: orvepitant, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 27
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Orange, California + 23 more

Conditions: Secondary Progressive Multiple Sclerosis
Interventions: Orelabrutinib, Placebo; Drug
Lead sponsor: Zenas BioPharma (USA), LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 990 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 27
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 23 more

Conditions: Post Traumatic Stress Disorder
Interventions: Modius Spero active device, Sham device; Device
Lead sponsor: Neurovalens Ltd.; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: Schizophrenia
Interventions: NaBen®, Placebo; Drug
Lead sponsor: SyneuRx International (Taiwan) Corp; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 20
States / cities: Dothan, Alabama • Bellflower, California • Long Beach, California + 17 more

Conditions: Major Depressive Disorder
Interventions: Placebo, Vilazodone; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 52
States / cities: Imperial, California • Los Angeles, California • Murrieta, California + 46 more

Conditions: Breast Neoplasms, Neoplasm Metastasis
Interventions: LY4064809, Placebo, Ribociclib, Palbociclib, Abemaciclib, Anastrozole, Letrozole, Exemestane, Fulvestrant; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 132
States / cities: Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 112 more

Conditions: Perimenopause
Interventions: Revive Product Form - Placebo Control, Revive Product Form - Active; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 37 Years to 55 Years · Female only
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Erectile Dysfunction
Interventions: placebo, avanafil; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 39
States / cities: Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 32 more

Conditions: Opioid Use Disorder
Interventions: Morphine, AZD4041, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Breast Cancer, Insomnia
Interventions: Suvorexant Tablets, Placebo Control; Drug · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Prostatic Neoplasms
Interventions: Pembrolizumab, Enzalutamide, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 28
States / cities: Mobile, Alabama • Fullerton, California • Los Angeles, California + 25 more

Conditions: HIV Infections
Interventions: Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil, Saquinavir, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more

Conditions: Healthy
Interventions: Vilazodone 20 mg, Vilazodone 40 mg, Paroxetine 20 mg, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 202 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 4
States / cities: Miami, Florida • Overland Park, Kansas • Saint Paul, Minnesota + 1 more

Conditions: Systemic Lupus Erythematosus
Interventions: DZP, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 16 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 60
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more

Conditions: Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma, Unilateral Breast Carcinoma
Interventions: Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine, Placebo Administration, Sargramostim; Drug · Other · Biological
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older · Female only
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 12
States / cities: Scottsdale, Arizona • Duarte, California • Jacksonville, Florida + 8 more

Conditions: Prostatic Neoplasms
Interventions: Niraparib+ Abiraterone acetate fixed dose combination (FDC), Abiraterone acetate (AA), Prednisone, Placebo FDC, Placebo AA; Combination Product · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 696 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 53
States / cities: Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more

Search by objective public record fields.

Study of Milnacipran for the Treatment of Fibromyalgia

Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

Safety and Tolerability of Glyceryl Tribenzoate (GTB) Capsules in Healthy Subjects

Moderate to Persistent Asthma in the Obese Subject

Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease

Evaluate the Effects of Citicoline on Mood in Healthy Adults

A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for PTSD

Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Radicle Revive™ CSP: A Trial Evaluating Plant-Based Health and Wellness Products on Perimenopausal Women's Self-Reported Health Issues and Outcomes

Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D)

A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.

Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient

Study to Evaluate the Sexual Functioning of Healthy Adults After Receiving Vilazodone, Paroxetine or Placebo

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)